First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population
Year: 2024
Type: article
Study design: Observational Study
Abstract: Aim: Assess first-line sunitinib dosing for treatment of metastatic renal cell carcinoma in Swedish clinical practice (2006–2019).Materials & methods: Retrospective analysis of three sunitinib dosing regimens: 2-weeks on, 1-week off (2:1 Start); standard 4-weeks on, 2-weeks off (4:2) and 4:2 start with switch to 2:1 (2:1 Switch).Results: Time-to-treatment discontinuation (95% CI) differed significantly (p < 0.001): 6.2 (5.6–7.2), 13.9 (8.1–20.6) and 4.6 (4.3–5.6) months for 2:1 Start (n = 320), 2:1 Switch (n = 71) and 4:2 (n = 704), respectively. Overall survival (95% CI) differed significantly (p < 0.001): 21.8 (18.1–26.1), 32.2 (25.1–48.3) and 13.5 (12.3–15.8) months for 2:1 Start (n = 320), 2:1 Switch (n = 71) and 4:2 (n = 704), respectively.Conclusion: Alternative dosing does not compromise clinical efficacy and may provide advantages in terms of improved treatment outcomes. However, due to the changing treatment patterns during this long-term study, and the absence of patient risk category data, caution is required when interpreting the main outcomes.
Source: Future Oncology
Institutions: Pfizer (Sweden), Toscana Life Sciences, ICON PLC (Ireland)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Pfizer
OpenAlex ID: W4403832466